Annalisa Jenkins

Welcome to Mereo BioPharma, we are an agile biopharmaceutical company, focused on finding and bringing to market therapies that will improve the lives of people living with a rare disease. We are driven by a true understanding of the critical nature of our mission. We harness the power of science; with our knowledge of the rare diseases we seek to treat and deep relationships with all our stakeholders to create new therapeutic possibilities for people who need them. We do this in a focused and capital efficient manner. Our journey began back in March 2015 fuelled by the desire to champion high-potential novel therapies that were not being progressed in pharmaceutical or biotechnology companies. We acquired three product candidates from Novartis in 2015 and one from AstraZeneca in 2017. Merging with OncoMed in 2019 strengthened our foundation, broadening our reach and adding cutting-edge oncology programs to our pipeline. The Mereo team is a crew on a mission. We understand the gravity of our work for people with few therapeutic options. Mereo’s agile approach is enabling us to move rigorously but quickly through trial programs. We have taken two therapies from in-licensing to pharma through to Phase 3 studies in under 5 years. Our portfolio covers potential therapies addressing critical needs in Osteogenesis Imperfecta (OI), Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) and two oncology product candidates. Our entrepreneurial spirit and purpose-led approach attracts the most talented people from across pharma and biotech. Every single team member is here because of their passion for helping people with health conditions, and their unique skills, experience and perspectives. We know what it takes to navigate reimbursement, which can be complex and have the expertise to drive excellence. Follow our updates on this extraordinary journey as we continue to collaborate with our stakeholders to forge new ways of doing things in rare disease.

MedCity is the life sciences cluster organisation for London, set up in 2014 by the Mayor of London and the city’s three Academic Health Science Centres. We are funded by the Greater London Authority and Research England, and as a not-for-profit are able to act as a neutral and independent convener across industry, academia and the public sector. London and the greater south east is home to a rich life sciences cluster, with more than 3,400 life sciences companies, four of the world’s top ten universities, 19 of the top 20 global pharmaceutical companies and world class research centres including The Francis Crick Institute, Harwell Oxford and The Sanger Institute. Our ambition is for our region to be the unequivocal place of choice for world-leading health and life sciences innovation, R&D, manufacture and commercialisation. Find out more at MedCityHQ.com or follow us on Twitter @MedCityHQ. Keep up to date with life sciences ecosystem news, thought leadership and opportunities through our newsletter – register here: https://www.medcityhq.com/newsletter

The Conscience Collective is a purpose-driven organisation dedicated to cultivating altruistic, impact-focused leadership in global health innovation. We empower the next generation of visionary CEOs and founders by connecting them with world-class mentors, strategic guidance, and valuable networks to help scale breakthrough health solutions that matter most in underserved communities worldwide. Our mission is to bridge the gap between bold ideas and real-world impact — fostering ethical, resilient leadership that drives sustainable, equitable change. Founded by Dr Annalisa Jenkins OBE, The Conscience Collective champions principled innovation and supports ambitious entrepreneurs in navigating the challenges of building scalable, socially responsible ventures.

Skye Bioscience (Nasdaq: SKYE) is focused on unlocking the pharmaceutical potential of the endocannabinoid system, initially through modulation of the CB1 receptor, to treat diseases with inflammatory, fibrotic, and metabolic processes.

K2 HealthVentures (K2HV) is an alternative investment firm that provides flexible, long-term financing solutions to innovative private and public companies in the life sciences and healthcare industries. We are healthcare specialists with deep domain expertise, and we understand both the opportunities and challenges that face venture-stage and growth-stage companies. Further, our flat organizational set-up enables nimble decision-making, and our evergreen fund structure allows us to be creative and adapt our facilities to a company’s specific needs over both the short and the long term. Over the last 4 years we have committed more than $1 billion in debt and equity capital to both private and public companies, and our team’s track record spans decades of investing in and supporting innovative life sciences and healthcare companies (with over $4 billion total investments in over 100 portfolio companies).

Welcome to Mereo BioPharma, we are an agile biopharmaceutical company, focused on finding and bringing to market therapies that will improve the lives of people living with a rare disease. We are driven by a true understanding of the critical nature of our mission. We harness the power of science; with our knowledge of the rare diseases we seek to treat and deep relationships with all our stakeholders to create new therapeutic possibilities for people who need them. We do this in a focused and capital efficient manner. Our journey began back in March 2015 fuelled by the desire to champion high-potential novel therapies that were not being progressed in pharmaceutical or biotechnology companies. We acquired three product candidates from Novartis in 2015 and one from AstraZeneca in 2017. Merging with OncoMed in 2019 strengthened our foundation, broadening our reach and adding cutting-edge oncology programs to our pipeline. The Mereo team is a crew on a mission. We understand the gravity of our work for people with few therapeutic options. Mereo’s agile approach is enabling us to move rigorously but quickly through trial programs. We have taken two therapies from in-licensing to pharma through to Phase 3 studies in under 5 years. Our portfolio covers potential therapies addressing critical needs in Osteogenesis Imperfecta (OI), Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) and two oncology product candidates. Our entrepreneurial spirit and purpose-led approach attracts the most talented people from across pharma and biotech. Every single team member is here because of their passion for helping people with health conditions, and their unique skills, experience and perspectives. We know what it takes to navigate reimbursement, which can be complex and have the expertise to drive excellence. Follow our updates on this extraordinary journey as we continue to collaborate with our stakeholders to forge new ways of doing things in rare disease.

The Kings Fund is an independent charity working to improve peoples health. Our vision is a world where everyone can live a healthy life. Our mission is to inspire hope and build confidence for positive change. We achieve this through expert insights and original research, developing leaders and their organisations, convening, and strategic, collaborative partnerships.